Iza-bren outperforms chemotherapy after EGFR TKI failure in NSCLC

The phase 3 PANKU-Lung01 trial compared izalontamab brengitecan, a bispecific EGFR/HER3 antibody-drug conjugate, with platinum-based chemotherapy in patients with EGFR-mutated advanced non-squamous NSCLC who progressed on third-generation EGFR TKIs. The trial reported median progression-free survival of 11.1 months with iza-bren versus 5.7 months with chemotherapy, but grade 3 or worse treatment-related adverse events were more frequent with iza-bren (79% vs 62%), including two cases of treatment-related interstitial lung disease versus none with chemotherapy.

Most relevant for: Patients with EGFR-mutated advanced non-squamous NSCLC whose disease has progressed after third-generation EGFR TKI therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.